NCT04775602View on ClinicalTrials.gov

Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.

PHASE2CompletedINTERVENTIONAL

Enrollment

550

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

April 5, 2023

Study Completion Date

July 11, 2024

Conditions

18F-PSMAProstate Cancer

Interventions

DRUG

18F-PSMA

18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)

Trial Locations (1)

47014

Irst Irccs, Meldola

All Listed Sponsors

lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

NCT04775602 - Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer. | Biotech Hunter | Biotech Hunter